“It is extremely chilling if, after spending a huge sum of money, time and effort to get a drug through FDA approval, you'll then have to go through it all again to see if CMS [Medicare] will pay for it,” said Allen S. Lichter, head of the American Society of Clinical Oncology.
It may be chilling, but this is exactly how the game is played in most of the world including, notably, the major countries of Europe.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.